ID   APOE_PAPAN              Reviewed;         317 AA.
AC   P05770; A0A096P2H8;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2017, sequence version 2.
DT   10-FEB-2021, entry version 115.
DE   RecName: Full=Apolipoprotein E;
DE            Short=Apo-E;
DE   Flags: Precursor;
GN   Name=APOE;
OS   Papio anubis (Olive baboon).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini;
OC   Cercopithecidae; Cercopithecinae; Papio.
OX   NCBI_TaxID=9555;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3220472; DOI=10.1016/0888-7543(88)90020-1;
RA   Hixson J.E., Cox L.A., Borenstein S.;
RT   "The baboon apolipoprotein E gene: structure, expression, and linkage with
RT   the gene for apolipoprotein C-1.";
RL   Genomics 2:315-323(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Liu Y.L., Abraham K.A., Akbar H.A., Ali S.A., Anosike U.A., Aqrawi P.A.,
RA   Arias F.A., Attaway T.A., Awwad R.A., Babu C.B., Bandaranaike D.B.,
RA   Battles P.B., Bell A.B., Beltran B.B., Berhane-Mersha D.B., Bess C.B.,
RA   Bickham C.B., Bolden T.B., Carter K.C., Chau D.C., Chavez A.C.,
RA   Clerc-Blankenburg K.C., Coyle M.C., Dao M.D., Davila M.L.D.,
RA   Davy-Carroll L.D., Denson S.D., Dinh H.D., Fernandez S.F., Fernando P.F.,
RA   Forbes L.F., Francis C.F., Francisco L.F., Fu Q.F., Garcia-Iii R.G.,
RA   Garrett T.G., Gross S.G., Gubbala S.G., Hirani K.H., Hogues M.H.,
RA   Hollins B.H., Jackson L.J., Javaid M.J., Jhangiani S.J., Johnson A.J.,
RA   Johnson B.J., Jones J.J., Joshi V.J., Kalu J.K., Khan N.K., Korchina V.K.,
RA   Kovar C.K., Lago L.L., Lara F.L., Le T.-K.L., Lee S.L., Legall-Iii F.L.,
RA   Lemon S.L., Liu J.L., Liu Y.-S.L., Liyanage D.L., Lopez J.L.,
RA   Lorensuhewa L.L., Mata R.M., Mathew T.M., Mercado C.M., Mercado I.M.,
RA   Morales K.M., Morgan M.M., Munidasa M.M., Ngo D.N., Nguyen L.N.,
RA   Nguyen T.N., Nguyen N.N., Obregon M.O., Okwuonu G.O., Ongeri F.O.,
RA   Onwere C.O., Osifeso I.O., Parra A.P., Patil S.P., Perez A.P., Perez Y.P.,
RA   Pham C.P., Pu L.-L.P., Puazo M.P., Quiroz J.Q., Rouhana J.R., Ruiz M.R.,
RA   Ruiz S.-J.R., Saada N.S., Santibanez J.S., Scheel M.S., Schneider B.S.,
RA   Simmons D.S., Sisson I.S., Tang L.-Y.T., Thornton R.T., Tisius J.T.,
RA   Toledanes G.T., Trejos Z.T., Usmani K.U., Varghese R.V., Vattathil S.V.,
RA   Vee V.V., Walker D.W., Weissenberger G.W., White C.W., Williams A.W.,
RA   Woodworth J.W., Wright R.W., Zhu Y.Z., Han Y.H., Newsham I.N.,
RA   Nazareth L.N., Worley K.W., Muzny D.M., Rogers J.R., Gibbs R.G.;
RT   "Whole genome assembly of Papio anubis.";
RL   Submitted (MAR-2012) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: APOE is an apolipoprotein, a protein associating with lipid
CC       particles, that mainly functions in lipoprotein-mediated lipid
CC       transport between organs via the plasma and interstitial fluids. APOE
CC       is a core component of plasma lipoproteins and is involved in their
CC       production, conversion and clearance. Apoliproteins are amphipathic
CC       molecules that interact both with lipids of the lipoprotein particle
CC       core and the aqueous environment of the plasma. As such, APOE
CC       associates with chylomicrons, chylomicron remnants, very low density
CC       lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but
CC       shows a preferential binding to high-density lipoproteins (HDL). It
CC       also binds a wide range of cellular receptors including the LDL
CC       receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and LRP8
CC       and the very low-density lipoprotein receptor/VLDLR that mediate the
CC       cellular uptake of the APOE-containing lipoprotein particles. Finally,
CC       APOE has also a heparin-binding activity and binds heparan-sulfate
CC       proteoglycans on the surface of cells, a property that supports the
CC       capture and the receptor-mediated uptake of APOE-containing
CC       lipoproteins by cells. A main function of APOE is to mediate
CC       lipoprotein clearance through the uptake of chylomicrons, VLDLs, and
CC       HDLs by hepatocytes. APOE is also involved in the biosynthesis by the
CC       liver of VLDLs as well as their uptake by peripheral tissues ensuring
CC       the delivery of triglycerides and energy storage in muscle, heart and
CC       adipose tissues. By participating in the lipoprotein-mediated
CC       distribution of lipids among tissues, APOE plays a critical role in
CC       plasma and tissues lipid homeostasis. APOE is also involved in two
CC       steps of reverse cholesterol transport, the HDLs-mediated transport of
CC       cholesterol from peripheral tissues to the liver, and thereby plays an
CC       important role in cholesterol homeostasis. First, it is functionally
CC       associated with ABCA1 in the biogenesis of HDLs in tissues. Second, it
CC       is enriched in circulating HDLs and mediates their uptake by
CC       hepatocytes. APOE also plays an important role in lipid transport in
CC       the central nervous system, regulating neuron survival and sprouting.
CC       {ECO:0000250|UniProtKB:P02649}.
CC   -!- SUBUNIT: Homotetramer. May interact with ABCA1; functionally associated
CC       with ABCA1 in the biogenesis of HDLs. May interact with APP/A4 amyloid-
CC       beta peptide; the interaction is extremely stable in vitro but its
CC       physiological significance is unclear. May interact with MAPT. May
CC       interact with MAP2. In the cerebrospinal fluid, interacts with secreted
CC       SORL1. {ECO:0000250|UniProtKB:P02649}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250|UniProtKB:P02649}.
CC       Secreted, extracellular space {ECO:0000250|UniProtKB:P02649}. Secreted,
CC       extracellular space, extracellular matrix
CC       {ECO:0000250|UniProtKB:P02649}. Note=In the plasma, APOE is associated
CC       with chylomicrons, chylomicrons remnants, VLDL, LDL and HDL
CC       lipoproteins. Lipid poor oligomeric APOE is associated with the
CC       extracellular matrix in a calcium- and heparan-sulfate proteoglycans-
CC       dependent manner. Lipidation induces the release from the extracellular
CC       matrix. {ECO:0000250|UniProtKB:P02649}.
CC   -!- PTM: APOE exists as multiple glycosylated and sialylated glycoforms
CC       within cells and in plasma. The extent of glycosylation and sialylation
CC       are tissue and context specific. {ECO:0000250|UniProtKB:P02649}.
CC   -!- PTM: Glycated in plasma VLDL. {ECO:0000250|UniProtKB:P02649}.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000250|UniProtKB:P02649}.
CC   -!- SIMILARITY: Belongs to the apolipoprotein A1/A4/E family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M29322; AAA35381.1; -; Genomic_DNA.
DR   EMBL; JH682906; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   PIR; A28792; A28792.
DR   RefSeq; XP_003918648.1; XM_003918599.2.
DR   SMR; P05770; -.
DR   STRING; 9555.ENSPANP00000019553; -.
DR   Ensembl; ENSPANT00000044903; ENSPANP00000042973; ENSPANG00000031383.
DR   eggNOG; ENOG502QVD6; Eukaryota.
DR   GeneTree; ENSGT00950000182929; -.
DR   OMA; ARLKGWF; -.
DR   OrthoDB; 1314660at2759; -.
DR   Proteomes; UP000028761; Unplaced.
DR   GO; GO:0042627; C:chylomicron; IEA:UniProtKB-KW.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0031012; C:extracellular matrix; ISS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; ISS:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0034364; C:high-density lipoprotein particle; ISS:UniProtKB.
DR   GO; GO:0034363; C:intermediate-density lipoprotein particle; ISS:UniProtKB.
DR   GO; GO:0034362; C:low-density lipoprotein particle; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:GOC.
DR   GO; GO:0043083; C:synaptic cleft; IEA:Ensembl.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; ISS:UniProtKB.
DR   GO; GO:0001540; F:amyloid-beta binding; ISS:UniProtKB.
DR   GO; GO:0016209; F:antioxidant activity; IEA:Ensembl.
DR   GO; GO:0120020; F:cholesterol transfer activity; IEA:Ensembl.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; ISS:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; ISS:UniProtKB.
DR   GO; GO:0071813; F:lipoprotein particle binding; IEA:Ensembl.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; ISS:UniProtKB.
DR   GO; GO:0046911; F:metal chelating activity; IEA:Ensembl.
DR   GO; GO:0060228; F:phosphatidylcholine-sterol O-acyltransferase activator activity; IEA:Ensembl.
DR   GO; GO:0005543; F:phospholipid binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
DR   GO; GO:0048156; F:tau protein binding; IEA:Ensembl.
DR   GO; GO:0070326; F:very-low-density lipoprotein particle receptor binding; IEA:Ensembl.
DR   GO; GO:0097113; P:AMPA glutamate receptor clustering; IEA:Ensembl.
DR   GO; GO:0042982; P:amyloid precursor protein metabolic process; IEA:Ensembl.
DR   GO; GO:0048844; P:artery morphogenesis; IEA:Ensembl.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0019934; P:cGMP-mediated signaling; IEA:Ensembl.
DR   GO; GO:0006707; P:cholesterol catabolic process; IEA:Ensembl.
DR   GO; GO:0033344; P:cholesterol efflux; ISS:UniProtKB.
DR   GO; GO:0042632; P:cholesterol homeostasis; IEA:Ensembl.
DR   GO; GO:0034382; P:chylomicron remnant clearance; ISS:UniProtKB.
DR   GO; GO:0055089; P:fatty acid homeostasis; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0010467; P:gene expression; IEA:Ensembl.
DR   GO; GO:0034380; P:high-density lipoprotein particle assembly; ISS:UniProtKB.
DR   GO; GO:0034384; P:high-density lipoprotein particle clearance; IEA:Ensembl.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; IEA:Ensembl.
DR   GO; GO:0071831; P:intermediate-density lipoprotein particle clearance; ISS:UniProtKB.
DR   GO; GO:0010877; P:lipid transport involved in lipid storage; IEA:Ensembl.
DR   GO; GO:0042158; P:lipoprotein biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0042159; P:lipoprotein catabolic process; IEA:Ensembl.
DR   GO; GO:0035641; P:locomotory exploration behavior; IEA:Ensembl.
DR   GO; GO:0015909; P:long-chain fatty acid transport; IEA:Ensembl.
DR   GO; GO:0007616; P:long-term memory; IEA:Ensembl.
DR   GO; GO:0034374; P:low-density lipoprotein particle remodeling; IEA:Ensembl.
DR   GO; GO:0051651; P:maintenance of location in cell; IEA:Ensembl.
DR   GO; GO:1905907; P:negative regulation of amyloid fibril formation; ISS:UniProtKB.
DR   GO; GO:1902430; P:negative regulation of amyloid-beta formation; IEA:Ensembl.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0045541; P:negative regulation of cholesterol biosynthetic process; IEA:Ensembl.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:1900272; P:negative regulation of long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IEA:Ensembl.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0010544; P:negative regulation of platelet activation; IEA:Ensembl.
DR   GO; GO:0050709; P:negative regulation of protein secretion; IEA:Ensembl.
DR   GO; GO:0090209; P:negative regulation of triglyceride metabolic process; IEA:Ensembl.
DR   GO; GO:0031175; P:neuron projection development; ISS:UniProtKB.
DR   GO; GO:0007263; P:nitric oxide mediated signal transduction; IEA:Ensembl.
DR   GO; GO:0097114; P:NMDA glutamate receptor clustering; IEA:Ensembl.
DR   GO; GO:0033700; P:phospholipid efflux; IEA:Ensembl.
DR   GO; GO:0044794; P:positive regulation by host of viral process; IEA:Ensembl.
DR   GO; GO:1900223; P:positive regulation of amyloid-beta clearance; ISS:UniProtKB.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; IEA:Ensembl.
DR   GO; GO:0010873; P:positive regulation of cholesterol esterification; IEA:Ensembl.
DR   GO; GO:0060999; P:positive regulation of dendritic spine development; IEA:Ensembl.
DR   GO; GO:1902952; P:positive regulation of dendritic spine maintenance; IEA:Ensembl.
DR   GO; GO:0045807; P:positive regulation of endocytosis; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:1905855; P:positive regulation of heparan sulfate binding; IEA:Ensembl.
DR   GO; GO:1905860; P:positive regulation of heparan sulfate proteoglycan binding; IEA:Ensembl.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IEA:Ensembl.
DR   GO; GO:1903002; P:positive regulation of lipid transport across blood-brain barrier; IEA:Ensembl.
DR   GO; GO:0032805; P:positive regulation of low-density lipoprotein particle receptor catabolic process; IEA:Ensembl.
DR   GO; GO:0051044; P:positive regulation of membrane protein ectodomain proteolysis; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IEA:Ensembl.
DR   GO; GO:1902995; P:positive regulation of phospholipid efflux; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0017038; P:protein import; IEA:Ensembl.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; IEA:Ensembl.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:2000822; P:regulation of behavioral fear response; IEA:Ensembl.
DR   GO; GO:0032489; P:regulation of Cdc42 protein signal transduction; IEA:Ensembl.
DR   GO; GO:1905890; P:regulation of cellular response to very-low-density lipoprotein particle stimulus; IEA:Ensembl.
DR   GO; GO:0045088; P:regulation of innate immune response; IEA:Ensembl.
DR   GO; GO:0061136; P:regulation of proteasomal protein catabolic process; IEA:Ensembl.
DR   GO; GO:0043254; P:regulation of protein-containing complex assembly; IEA:Ensembl.
DR   GO; GO:0061771; P:response to caloric restriction; IEA:Ensembl.
DR   GO; GO:0002021; P:response to dietary excess; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0043691; P:reverse cholesterol transport; IEA:Ensembl.
DR   GO; GO:0070328; P:triglyceride homeostasis; IEA:Ensembl.
DR   GO; GO:0006641; P:triglyceride metabolic process; IEA:Ensembl.
DR   GO; GO:0071830; P:triglyceride-rich lipoprotein particle clearance; ISS:UniProtKB.
DR   GO; GO:0042311; P:vasodilation; IEA:Ensembl.
DR   GO; GO:0034447; P:very-low-density lipoprotein particle clearance; ISS:UniProtKB.
DR   GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; IEA:Ensembl.
DR   GO; GO:0019068; P:virion assembly; IEA:Ensembl.
DR   InterPro; IPR000074; ApoA_E.
DR   Pfam; PF01442; Apolipoprotein; 1.
PE   3: Inferred from homology;
KW   Chylomicron; Extracellular matrix; Glycoprotein; HDL; Heparin-binding;
KW   Lipid transport; Lipid-binding; Oxidation; Phosphoprotein;
KW   Reference proteome; Repeat; Secreted; Signal; Transport; VLDL.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..317
FT                   /note="Apolipoprotein E"
FT                   /id="PRO_0000001992"
FT   REPEAT          80..101
FT                   /note="1"
FT   REPEAT          102..123
FT                   /note="2"
FT   REPEAT          124..145
FT                   /note="3"
FT   REPEAT          146..167
FT                   /note="4"
FT   REPEAT          168..189
FT                   /note="5"
FT   REPEAT          190..211
FT                   /note="6"
FT   REPEAT          212..233
FT                   /note="7"
FT   REPEAT          234..255
FT                   /note="8"
FT   REGION          80..255
FT                   /note="8 X 22 AA approximate tandem repeats"
FT   REGION          158..168
FT                   /note="LDL and other lipoprotein receptors binding"
FT                   /evidence="ECO:0000250|UniProtKB:P02649"
FT   REGION          162..165
FT                   /note="Heparin-binding"
FT                   /evidence="ECO:0000250|UniProtKB:P02649"
FT   REGION          210..290
FT                   /note="Lipid-binding and lipoprotein association"
FT                   /evidence="ECO:0000250|UniProtKB:P02649"
FT   REGION          229..236
FT                   /note="Heparin-binding"
FT                   /evidence="ECO:0000250|UniProtKB:P02649"
FT   REGION          266..317
FT                   /note="Homooligomerization"
FT                   /evidence="ECO:0000250|UniProtKB:P02649"
FT   REGION          278..290
FT                   /note="Specificity for association with VLDL"
FT                   /evidence="ECO:0000250|UniProtKB:P02649"
FT   MOD_RES         143
FT                   /note="Methionine sulfoxide"
FT                   /evidence="ECO:0000250|UniProtKB:P08226"
FT   MOD_RES         147
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P02649"
FT   CONFLICT        31..32
FT                   /note="EL -> DV (in Ref. 1; AAA35381)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   317 AA;  36021 MW;  3DCF7AEA1F22E48E CRC64;
     MKVLWAALLV TFLAGCQAKV EQPVEPETEP ELRQQAEWQS GQPWELALGR FWDYLRWVQT
     LSEQVQEELL SPQVTQELTT LMDETMKELK AYKSELEEQL SPVAEETRAR LSKELQAAQA
     RLGADMEDVR SRLVQYRSEV QAMLGQSTEE LRARLASHLR KLRKRLLRDA DDLQKRLAVY
     QAGAREGAER GVSAIRERLG PLVEQGRVRA ATVGSLASQP LQERAQALGE RLRARMEEMG
     SRTRDRLDEV KEQVAEVRAK LEEQAQQISL QAEAFQARLK SWFEPLVEDM QRQWAGLVEK
     VQAAVGASTA PVPSDNH
//
